Antihypertensive use before and after initiation of fixed-dose combination products in Australia: A retrospective study

International Journal of Clinical Pharmacy

Volumn 35, Issue 4, 2013, Pages 613-620

  Gadzhanova, Svetla ^a   Ilomäki, Jenni ^a   Roughead, Elizabeth E ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Aged; Antihypertensive agents; Australia; Combination therapy; Drug utilisation; Elderly epidemiology; Veterans

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; FELODIPINE; FELODIPINE PLUS RAMIPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; OLMESARTAN; RAMIPRIL; VALSARTAN;

AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG INDICATION; FEMALE; FIXED DOSE COMBINATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VETERAN;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; COHORT STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VETERANS;

EID: 84881137962     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9782-z     Document Type: Article

References (31)

1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404. (Pubitemid 35469393)
2. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
3. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J (Clin Res Ed). 2003;326:1427.
4. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, Laurent S, Mancia G, Ruilope LM, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract. 2007;61:1592-602. (Pubitemid 47228597)
5. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med J Aust. 2011;195:134-7.
6. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
7. Horn FE, Mandryk JA, Mackson JM, Wutzke SE, Weekes LM, Hyndman RJ. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf. 2007;16:297-308. (Pubitemid 46431692)
8. Byrd JB, Zeng C, Tavel HM, Magid DJ, O'Connor PJ, Margolis KL, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162:340-6.
9. Walker RL, Chen G, Campbell NR, McAlister FA, Quan H, Tu K, et al. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. Can J Cardiol. 2011;27:461-7.
10. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens. 2009;27:2121-58.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72. (Pubitemid 37430158)
12. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al. The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27:415-33.
13. Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006;48:416-25.
14. Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2007;65:795-6. (Pubitemid 351535085)
15. Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British women's heart and health study. Age Ageing. 2010;39:51-6.
16. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173-8. (Pubitemid 41583613)
17. Gangavati A, Hajjar I, Quach L, Jones RN, Kiely DK, Gagnon P, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59:383-9.
18. Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology. 2010;21:658-68.
19. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739-44.
20. Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS ONE. 2009;5:e5521.
21. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J. 2010;31:85-91.
22. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010. National Heart Foundation of Australia; 2010.
23. National Prescribing Service. Managing hypertension as a cardiovascular risk factor. Strawberry Hills: National Prescribing Service Limited; 2007.
24. National Prescribing Service. Olmesartan medoxomil (Olmetec) monotherapy or in combination with hydrochlorothiazide (Olmetec Plus) for hypertension: National Prescribing Service Limited; 2007.
25. National Prescribing Service. Be aware of dose ranges for new ramipril with felodipine combination (Triasyn). National Prescribing Service Limited; 2007.
26. National Prescribing Service. Valsartan (Diovan) and combinations with hydrochlorothiazide (Co-Diovan) or amlodipine (Exforge). National Prescribing Service Limited; 2009.
27. Australian Prescriber. New combinations enalapril maleate/ hydrochlorothiazide. Australian Prescriber. 2001;24: p 203.
28. Australian Government Department of Health and Ageing. Formulary allocations 1 Oct 2012. Canberra: Department of Health and Ageing; 2012 [cited 2012 Oct 29]; Available from: http://www.pbs.gov.au/info/industry/pricing/pbs- items/formulary-allocations.
29. Lloyd J, Anderson P. Australian institute of health and welfare. Veterans' use of health services. Canberra: AIHW; 2008.
30. Australian Government Department of Veterans' Affairs. Treatment population statistics December 2011. Canberra: Australian Government Department of Veterans' Affairs; 2011.
31. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification system. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. 2012 [cited 2012 Oct 29]. Available from: http://www.whocc.no/atcddd/.